Posted by Michael Wonder on 19 Aug 2021
Miravo Healthcare announces receipt of Health Canada Notice of Compliance for the paediatric use of Blexten
12 August 2021 - Blexten Label Expanded to Include Ages as Young as 4 Years Old.
Nuvo Pharmaceuticals today announced Health Canada has issued a Notice of Compliance in relation to the Company’s supplement to new drug submission for the paediatric use of Blexten.
The paediatric use includes the approval of two new dosage formats; a 2.5 mg/mL oral solution and 10 mg quick melt tablets.
